论文部分内容阅读
目的:探讨分析采用拉米夫定治疗慢性乙型肝炎的临床效果与相关药理。方法:选取我院2012年1月-2013年12月收治的86例慢性乙型肝炎患者为研究对象,将其随机平均分成两组,对照组43例患者给予阿德福韦酯治疗,观察组43例患者给予拉米夫定治疗,观察两组治疗效果。结果:观察组患者治疗12周后其乙型肝炎病毒DNA(HBV-DNA)转阴率为79.1%,血清转氨酶(ALT)复常率为65.1%;对照组患者HBV-DNA转阴率为46.5%,ALT复常率为30.2%,两组比较差异具有统计学意义(p<0.05)。结论:采用拉米夫定治疗慢性乙型肝炎的临床效果较显著,能有效抑制乙肝病毒的复制,恢复ALT恢复到正常水平,有效提高患者生活质量,值得应用。
Objective: To investigate the clinical effect and related pharmacology of chronic hepatitis B treated with lamivudine. Methods: Totally 86 chronic hepatitis B patients admitted to our hospital from January 2012 to December 2013 were selected and divided into two groups randomly. In the control group, 43 patients were treated with adefovir dipivoxil, and the observation group Forty-three patients were treated with lamivudine, and the therapeutic effects were observed. Results: In the observation group, the HBV-DNA negative conversion rate was 79.1% and the serum ALT normalization rate was 65.1% after 12 weeks of treatment. In the control group, the HBV-DNA negative conversion rate was 46.5 %, The recovery rate of ALT was 30.2%, the difference between the two groups was statistically significant (p <0.05). Conclusion: The clinical effect of lamivudine treatment of chronic hepatitis B is more significant, which can effectively inhibit the replication of hepatitis B virus, restore the normal ALT level, and effectively improve the quality of life of patients.